SCHEMBL12427062

SCHEMBL12427062

COc1nc(-c2ccccc2)ccc1CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 5/20 0.53
CD274 Q9NZQ7 9/20 0.52
PDCD1 Q15116 8/20 0.52
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HPGD P15428 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 3/20 0.48
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 3/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427066 0.84 HSD17B10 (0.50) SQORCD274PDCD1RAB9ANPC1
SCHEMBL12427065 0.83 HPGD (0.49) SQORCD274PDCD1RAB9ANPC1
SCHEMBL12427075 0.83 HPGD (0.59) SQORCD274PDCD1RAB9ANPC1
SCHEMBL14931897 0.83 PDCD1 (0.41) SQORCD274PDCD1RAB9ANPC1
SCHEMBL12427074 0.83 SQOR (0.39) SQORCD274PDCD1RAB9ANPC1
SCHEMBL17450996 0.82 RAB9A (0.48) SQORCD274PDCD1RAB9ANPC1
SCHEMBL12427069 0.80 TRPV3 (0.45) TDO2
SCHEMBL12427073 0.79 TRPV3 (0.46) CD274PDCD1NPSR1HPGDKDM4E
SCHEMBL27261381 0.78 CLK2 (0.44) CD274PDCD1LG2
SCHEMBL12427076 0.78 SOAT1 (0.44) HPGDL3MBTL1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG SQOR 1609/4885CD274 2428/4885PDCD1 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.